Dr. Rothstein is a Professor of Neurology and Neuroscience at Johns Hopkins University.  He is the Founder and Director of the Robert Packard Center for ALS Research and the Director of the Brain Science Institute and the Founder and Co-Director of the ALS Clinic. His lab first discovered that excitotoxicity might be a common pathophysiological process in sporadic ALS.  His lab, in collaboration with Ionis pharma, discovered on the development of antisense oligonucleotides therapy for C9 ALS/FTD patients. He made discoveries on fundamental pathways that underlay familial and sporadic ALS, including excitotoxicity, astroglial dysfunction, oligodendroglial dysfunction and the role of nuclear pore complex and nucleocytoplasmic transport in familial and sporadic ALS. He is the author of more than 350 research articles on ALS pathophysiology and basic neuroscience.  He is funded by the NIH, Dept of Defense and leading ALS nonprofits. He is the founder and Director of the Answer ALS program, which combines longitudinal clinical data, at-home smartphone data collection and the generation of iPS neurons from form more than 1000 USA ALS patients and their comprehensive biological analytics, leading to a data set of 6 billion biological and clinical data points per patient.  The data is freely accessible worldwide to academic and commercial researchers, intended to advance ALS discovery, biomarkers and drug development.